Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, September 27, 2022
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
[ Tue, Sep 27th 2022
] - WOPRAI
Mon, September 26, 2022
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
[ Mon, Sep 26th 2022
] - WOPRAI
Raghuram Selvaraju Maintained (SPRO) at Strong Buy with Decreased Target to $6 on, Sep 26th, 2022
Raghuram Selvaraju of HC Wainwright & Co., Maintained "Spero Therapeutics, Inc." (SPRO) at Strong Buy with Decreased Target from $7 to $6 on, Sep 26th, 2022.
Raghuram has made no other calls on SPRO in the last 4 months.
There is 1 other peer that has a rating on SPRO. Out of the 1 peers that are also analyzing SPRO, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Josh Schimmer of "Evercore ISI Group" Upgraded from Hold to Buy and Increased Target to $8 on, Friday, September 23rd, 2022
